Evaluation of adapalene alone versus combination therapy of adapalene with benzoyl peroxide and adapalene with clindamycin in treatment of acne vulgaris: a prospective, observational study

Authors

  • Nehal R. Parikh Department of Pharmacology, Smt. Nathiba Hargovandas Lakhmichand Municipal Medical College, Ellis-bridge, Ahmedabad, Gujarat, India
  • Shikha V. Sood Department of Pharmacology, Smt. Nathiba Hargovandas Lakhmichand Municipal Medical College, Ellis-bridge, Ahmedabad, Gujarat, India
  • Devang Rana Department of Pharmacology, Smt. Nathiba Hargovandas Lakhmichand Municipal Medical College, Ellis-bridge, Ahmedabad, Gujarat, India
  • Raju Chaudhary Department of Dermatology, Smt. Nathiba Hargovandas Lakhmichand Municipal Medical College, Ellis-bridge, Ahmedabad, Gujarat, India
  • Supriya D. Malhotra Department of Dermatology, Smt. Nathiba Hargovandas Lakhmichand Municipal Medical College, Ellis-bridge, Ahmedabad, Gujarat, India

DOI:

https://doi.org/10.18203/issn.2455-4529.IntJResDermatol20194677

Keywords:

Acne vulgaris, Adapalene, Benzoyl peroxide, CADI, Clindamycin

Abstract

Background: Acne vulgaris is majorly affecting adolescent population with profound negative impact on the quality of life (QOL). The objectives of the present study was to evaluate adapalene 0.1% alone vs combination therapy of adapalene 0.1% with benzoyl peroxide (BPO) 2.5% and adapalene 0.1% with clindamycin 1% in the treatment of acne vulgaris and to analyse health related QOL using the cardiff acne disability index (CADI).

Methods: This prospective, observational study of 12 months duration involved patients who were being treated with adapalene alone and adapalene combined with either clindamycin or benzoyl peroxide in the normal course of treatment. Efficacy of treatment and QOL was assessed by the comprehensive acne severity system (CASS) and CADI respectively.

Results: A total of 180 patients were enrolled (n=60 in each group). Male: female ratio was 1: 2.52. 76.7% patients were of adolescent age with the Mean age of 21.17±3.28 years. Average age of onset was 18.03±2.80 years. Most patients had moderate grade of acne (51%) followed by mild grade (46%) and almost clear (3%). Face was the common site, followed by back and chest. There was a statistically significant improvement in both number of lesions and also QOL in all the three treatment groups (p<0.0001).

Conclusions: Topical adapalene 0.1% is efficacious in the treatment of acne vulgaris both alone as well as in combination with topical benzoyl peroxide 2.5% and topical clindamycin 1%. Adapalene also has positive influence on the QOL alone as well as in combination but no superiority of one group over the other was observed with regard to efficacy as well as QOL.

 

References

IADVL’s Concise Textbook of Dermatology. In: Vishwanath V., ed. Grades of Acne. Wiley Blackwell; 2012: 16: 195: Table 16.1.

Adityan B, Kumari R, Thappa DM. Scoring systems in acne vulgaris. Indian J Dermatol Venereol Leprol. 2009;75:323-6.

Finlay AY. Quality of life indices. Indian J Dermatol Venereol Leprol. 2004;70:143-8.

Kumar S, Dutta S, Beg MA, Mehta AK, Anjoom M, Sindhu S. Drug utilization pattern in acne vulgaris in skin outpatients department. Int J Med Sci Public Health. 2014;3:855-8.

Patro N, Jena M, Panda M, Dash M. A Study on the prescribing pattern of drugs for acne in a tertiary care teaching hospital in Odisha. J Clin Diagnost Res. 2015;9(3):4-6.

Krishnaswamy K, Kumar DB, Radhaiah G. A drug use survey- precepts and practice. Eur J Clin Pharmacol. 1985;29:363-70.

Alvarez-Elroco S, Enzler MJ. The macrolides. erythromycin, clarithromycin, and azithromycin. Mayo Clin Proc. 1999;74:613-34.

Parsad D, Pandhi R, Nagpal R, Negiks. Azithromycin monthly pulses VS daily doxycyline in the treatment of acne vulgaris. J Dermatol. 2001;28(7):7-4.

Yap FBB. The impact of acne vulgaris on the quality of life in Sarawak, Malaysia. J Saudi Societ Dermatol Dermatol Surg. 2012;16:57-60.

Biju V. Acne, rosacea and perioral dermatitis. In: Vasudevan B, Chatterjee M, eds. IADVL Textbook and atlas of dermatology. Kathmandu: Jaypee Borthers Medical Publishers (P) Ltd; 2003: 2: 689-710.

Kubota Y, Munehiro A, Shirahige Y, Nakai K, Katsuura J, Moriue T, et al. Effect of sequential application of topical adapalene and clindamycin phosphate in the treatment of Japanese patients with acne vulgaris. J Dermatol Treatment. 2011;23(1):37-45.

Gollnick HP, Draelos Z, Glenn MJ, Rosoph LA, Kaszuba A, Cornelison R, et al. Adapalene-benzoyl peroxide a unique fixed-dose combination topical gel for the treatment of acne vulgaris: a transatlantic, randomized, double-blind, controlled study. Br J Dermatol. 2009;161(5):1180-9.

Layton AM, Eady EA. Benzoyl peroxide and adapalene fixed combination: a novel agent for acne. Br J Dermatol. 2009;161(5):971-6.

Tan JKL. Adapalene 0.1% and benzoyl peroxide 2.5%: combination for treatment of acne vulgaris. Skin Therapy Lett. 2009;14(6):4-5.

Shroot B. Pharmacodynamics and pharmacokinetics of topical adapalene. J Am Acad Dermatol. 1998;39:S17-24.

Cove JH, Holland KT. The effect of benzoyl peroxide on cutaneous microorganisms in vitro. J Appl Bacteriol. 1983;54(3):379-82.

Bojar RA, Cunliffe WJ, Holland KT. The short-term treatment of acne vulgaris with benzoyl peroxide: effects on the surface and follicular cutaneous microflora. Br J Dermatol. 1995;132(2):204-8.

Tenaud I, Khammari A, Dreno B. In vitro modulation of TLR-2, CD1d and IL-10 by adapalene on normal human skin and acne inflammatory lesions. Exp Dermatol. 2007;16(6):500-6.

Prasad S, Mukhopadhyay A, Kubavat A, Kelkar A, Modi A, Swarnkar B, Bajaj B, Vedamurthy M, Sheikh S, Mittal R. Indian J Dermatol, Venereol and Leprol. 2012;78(4): 459‑67.

Yap FB. Cardiff acne disability index in Sarawak, Malaysia. Ann Dermatol. 2012;24(2):158.

Tan JK, Tang J, Fung K, Gupta AK, Thomas DR, Sapra S, et al. Development and validation of a comprehensive acne severity scale. J Cutaneous Med Surg. 2007;11(6):211-6.

Wolf JE, Kaplan D, Kraus SJ, Loven KH, Rist T, Swinyer LJ, et al. Efficacy and tolerability of combined topical treatment of acne vulgaris with adapalene and clindamycin. J Am Acad Dermatol. 2003;49(3):S211-7.

Thiboutot D, Zaenglein A, Weiss J, Webster G, Calvarese B, Chen D. J Am Acad Dermatol. 2008;59(5):792-800.

Reddy NB, Nandimath MK. Comparision of clinical efficacy of topical clindamycin with adapalene and adapalene alone in treatment of mild to moderate facial acne vulgaris. Int J Pharm Bio Sci. 2013;4(3):1079-88.

Jain VK, Chopra KL, Dayal S. Comparative evaluation of topical benzoyl peroxide, metronidazole and benzoyl peroxide - clindamycin combination in treatment of acne vulgaris. Indian J Dermatol Venerol Leprol. 1998;64(2):71-4.

Layton AM. Rook’s Textbook of Dermatology. In: Burns T, Breathnach S, Cox N, Griffiths C, eds. 8th ed. USA: Wiley-Blackwell Publication; 2010: 42.17.

Keating GM. Adapalene 0.1%/ benzoyl peroxide 2.5% gel. Am J Clin Dermatol. 2011;12(6):407-20.

Babaeinejad SH, Fouladi RF. The efficacy, safety and tolerability of adapalene versus benzoyl peroxide in the treatment of mild acne vulgaris. J Drugs Dermatol. 2013;12(7):790-4.

Shwetha H, Geetha A, Revathi T. A comparative study of efficacy and safety of combination of topical 1% clindamycin and 0.1% adapalene with 1% clindamycin and 2.5% benzoyl peroxide in mild to moderate acne at a tertiary care hospital. J Chem Pharm Res. 2014;6(2):736-41.

Mallon E, Newton JN, Klassen A, Stewart-Brown SL, Ryan TJ, Finlay AY. The quality of life in acne: a comparison with general medical conditions using generic questionnaires. Br J Dermatol. 1999;140(4):672-6.

Chandani K, Raval R, Rana D, Malhotra S. Study of drug use pattern and analysis of quality of life in patients of acne attending the dermatology OPD. Natl J Integr Res Med. 2018;9(1):108-16.

Downloads

Published

2019-10-21

Issue

Vol. 5 No. 4 (2019): October-December 2019

Section

Original Research Articles